Solid Biosciences raises $240 million in private placement

Solid Biosciences Inc. (NASDAQ: SLDB) announced it entered into a securities purchase agreement for approximately $240 million in a private placement with institutional investors. The transaction is expected to close on or about March 9, 2026, subject to customary closing conditions.

The company is selling 14,973,257 shares of common stock at $5.61 per share and pre-funded warrants to purchase up to 27,807,482 shares at $5.609 per warrant. The pre-funded warrants carry an exercise price of $0.001 per share and are exercisable immediately until exercised in full.

The private placement includes participation from existing and new investors such as Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital.

Solid Biosciences plans to use the net proceeds to fund ongoing pipeline development programs, business development activities, working capital and general corporate purposes. The company develops precision genetic medicines for neuromuscular and cardiac diseases.

Leerink Partners and Citigroup serve as joint lead placement agents, while Cantor acts as co-lead placement agent. Truist and H.C. Wainwright & Co. are co-placement agents for the financing.

The securities have not been registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or an applicable exemption. The company agreed to file a registration statement with the Securities and Exchange Commission for the resale of shares within 30 days after closing.

You May Also Be Interested In

• Alliance Laundry principal stockholder prices 22.55M share offering
• CXApp acquires Australian firm EngineRoom in June 2026 deal
• Interstate Power and Light prices $500 million in senior debentures